CLYM (29) IRWD (63) ACRS (19) NVCT (37) ⌘ Pro Terminal →

CorMedix Inc. (CRMD) — RQD Stock Rating Cockpit

$5.70 -25.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.43

CorMedix Inc. (CRMD) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $595.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, CorMedix Inc. (NASDAQ: CRMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $5.70 (-25.46% 1D, market cap $595.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, CRMD ranks #162 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRMD compare to CLYM and IRWD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRMD carries a Roarable C (62/100 RQD), trailing P/E of 3.7x, gross margin of 88.5%, and ROIC of 45.5%. By comparison, CLYM (Climb Bio Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $593.3M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C grade (63/100 RQD, P/E 24.9x, ROIC 85.0%, cap $598.2M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRMD?

▼

Per CRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001410098), CorMedix Inc. generated $311.7M in revenue (+617.0% YoY), $163.1M in net income, and $172.8M in free cash flow against $826.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (89% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.43 (-4.77%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 55.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRMD)Realized 20D OHLCV Swing Band: ±11.7%

Deterministic 5-Pillar Attribution (62/100 Composite)

🔍 WHY CRMD SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 55.4% FCF Margin ($172.8M FCF) & 88.5% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$7.46-1.1% Next Q

Q2 (-2Q)

Grade B-$7.38+7.6% Next Q

Q3 (-1Q)

Grade C+$7.94-28.2% Next Q

Current

Grade C$5.70+0.7% Hist 90D α

Trajectory: B (70) → C (62)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CRMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, CRMD faces multiple-compression risk if 3.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 86.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($7.79) or 200D SMA ($7.68) invalidates the momentum regime and cuts Target Base ($5.80) toward Bear Floor ($4.52).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 62%NO 38%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

50.630 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

1.81>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $6$5.70H: $13

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (89% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 22 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on CRMD

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (80)

45.5% ROIC with 88.5% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 1.81 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (53)

22/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like CRMD

✓Strong cash generator (89% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CRMD Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.85%▼ SUPPORT BREAKDOWN

2026-11-02O $8.20H $8.20L $5.70C $5.70VOL 1.89M

RES: $8.33SUP: $6.36SMA50: $7.79SMA200: $7.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRMD Butterfly Map → + Track CRMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-15.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRMD)

Health Care Rank #162 of 1016 ⚔️ CLYM vs CRMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRMD vs. CLYM, IRWD, ACRS, NVCT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CorMedix Inc. (CRMD) ranks #162 by composite RQD confidence (62/100, grade C) and #422 by equity capitalization ($595.5M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with CRMD at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRMD ACTIVE CorMedix Inc.	C	62/100	3.7x	88.5%	45.5%	-25.46%	$595.5M	Benchmark Subject
CLYM Climb Bio Inc.	E	29/100	—	—	-35.0%	-0.77%	$593.3M	/clym-vs-crmd →
IRWD Ironwood Pharmaceuticals Inc. (Class A)	C	63/100	24.9x	—	85.0%	-3.31%	$598.2M	/irwd-vs-crmd →
ACRS Aclaris Therapeutics Inc.	E	19/100	—	73.3%	-35.0%	-0.50%	$587.3M	/acrs-vs-crmd →
NVCT Nuvectis Pharma Inc.	D-	37/100	—	—	-35.0%	-0.48%	$605.6M	/nvct-vs-crmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001410098

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CorMedix Inc. (CRMD) reported GAAP revenue of $311.7M (+617.0% vs. FY2024 revenue of $43.5M ) , GAAP net income of $163.1M, operating cash flow of $175.0M, and free cash flow of $172.8M (+440.6% YoY). On the balance sheet, CRMD closed FY2025 with $826.1M in total assets against $0 in total debt (Altman Z-Score: 1.81, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$311.7M	$163.1M	$175.0M	$172.8M	$826.1M	—
FY2024 (FY)	2024-12-31	$43.5M	-$17.9M	-$50.6M	-$50.7M	$118.8M	—
FY2023 (FY)	2023-12-31	$0	-$46.3M	-$38.4M	-$38.4M	—	—

3. CRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CRMD compare to CLYM and IRWD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CRMD?

Where is CRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

CRMD last traded at $5.70 (-25.46% on volume of 7,017,416 shares), positioning the stock -26.83% below its 50-day simple moving average ($7.79) and -25.78% below its 200-day simple moving average ($7.68). Across its 52-week range of $5.63 to $13.02, CRMD sits at the 0.9% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($5.03 to $6.37).

CRMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CRMD stock right now?

CorMedix Inc. (CRMD) currently earns a Roarable Rating of C (Hold — HOLD) with 62/100 RQD Confidence. Solid 89% profit margin (46% return on capital), mixed timing at 4x P/E—hold if owned, no rush to chase.

What is CRMD's 12-month price target and RQD AI Jury consensus?

CRMD's 12-month base price target is $5.8 (range $4.52 to $13.67), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CRMD RQD Cockpit CRMD 12M Forecast CRMD Earnings & Move CRMD Dividends & DRIP CRMD Insiders & 13F CRMD Whale Options CRMD Profit Sankey CRMD News & Why